RECRUITING

Enhancing Telemedicine for T2D

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this pilot clinical trial is to assess feasibility of an intervention to deliver comprehensive, high-quality diabetes care through telemedicine among adults with type 2 diabetes who use insulin and have multiple chronic health conditions. The main question it aims to answer is: Is an enhanced telemedicine intervention for type 2 diabetes compared to usual telemedicine care feasible? Researchers will compare the enhanced telemedicine intervention to usual telemedicine care to see if there are differences in patient satisfaction or preliminary clinical outcomes. Participants will complete 2-3 telemedicine diabetes care visits over approximately 6 months, as well as complete survey measures with each diabetes care visit. Patients in the intervention group will also receive additional support, including pre-visit preparation phone calls, diabetes self-management education and support aligned with their visits, and post-visit follow-up calls.

Official Title

Pilot Study Enhancing Telemedicine Care Delivery for Adults With Complex Type 2 Diabetes

Quick Facts

Study Start:2025-02-03
Study Completion:2026-07-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06740435

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * adults 18 years or older
  2. * Diagnosis of type 2 diabetes based on abbreviated ICD-10 code E11.X in medical record or self-report
  3. * HbA1c greater than or equal to 8% based on most recent value at time of recruitment
  4. * Patients must own or have access to a smart phone, tablet, or home computer with data or internet connection that allows access to video-based visits
  5. * Patient must use insulin
  6. * Patients must have \>2 comorbid chronic health conditions
  7. * Be able to provide informed consent
  1. * Age over 80 based on date of birth in electronic medical record
  2. * Visit with an endocrinologist in the prior 3 years
  3. * Dementia, ESRD, malignancy based on abbreviated ICD-10 codes below in medical record or self-report of associated condition
  4. * Dementia: A81.0x, F01.5x, F02.8x, F03.9x, F10.27, F10.97, F13.27, F13.97, F18.97, F19.17, F19.27, F19.97, G30.x, G31.0x, G31.1, G31.83, G31.85
  5. * Malignancy, except non-melanoma skin cancer: C00.x-C14.x, C15.x-C26.x, C3x.xx, C40.xx-C41.x, C43.x, C4A.xx, C45.x-C49.xx, C50.xxx, C51.x-C58, C60.x-C63.x, C64.x- C68.x, C69.xx-C72.x, C73-C76.x, C7A.xx, C80.xx-C96.x (except C90.x1, C91.x1, C92.x1, C93.x1, C94.x1, C95.x1)
  6. * ESRD N18.6
  7. * Type 1, gestational, or other diabetes based on abbreviated ICD-10 codes below in medical record or self-report of associated condition
  8. * Type 1 diabetes: E10.X
  9. * Gestational diabetes: O24.X, E08.X
  10. * Other diabetes: E09.X, E13.2
  11. * Pregnant or planning to become pregnant in next 6 months
  12. * Currently enrolled in another diabetes management intervention study

Contacts and Locations

Study Contact

Margaret Zupa, MD MS
CONTACT
412-648-4660
zupamf@pitt.edu

Principal Investigator

Margaret Zupa, MDMS
PRINCIPAL_INVESTIGATOR
University of Pittsburgh

Study Locations (Sites)

University of Pittsburgh
Pittsburgh, Pennsylvania, 15213
United States

Collaborators and Investigators

Sponsor: University of Pittsburgh

  • Margaret Zupa, MDMS, PRINCIPAL_INVESTIGATOR, University of Pittsburgh

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-03
Study Completion Date2026-07-30

Study Record Updates

Study Start Date2025-02-03
Study Completion Date2026-07-30

Terms related to this study

Keywords Provided by Researchers

  • Telemedicine

Additional Relevant MeSH Terms

  • Type 2 Diabetes